KLK3 and prostate cancer: While PSA is highly active in the seminal fluid and in the ECF of prostate cancers [3–6], it is inactivated in the bloodstream of patients due to the covalent binding to the abundant serum protease inhibitors α-1-antichymotrypsin and α-2-macroglobulin [7, 8].